Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's ... The Pharma Letter Also at ASCO yesterday, Swiss drug major Novartis (NOVN: VX) presented results from a pivotal Phase III trial of a treatment regimen including Afinitor (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) ... |
